Supportive Care in Cancer, Год журнала: 2025, Номер 33(6)
Опубликована: Июнь 1, 2025
Язык: Английский
Journal of Clinical Medicine, Год журнала: 2025, Номер 14(7), С. 2449 - 2449
Опубликована: Апрель 3, 2025
Background: Myasthenia gravis (MG) and idiopathic inflammatory myopathy (IIM) are autoimmune diseases that affect the musculoskeletal system. The association of two is rare. Their management different, so it important to recognize concomitant presentation. Methods: In this cross-sectional study, we study presence CK elevation, myositis-specific myositis-associated antibodies (MSA/MAA), vitamin D levels in a cohort 101 MG patients. Electromyography, limb magnetic resonance imaging (MRI), and, some cases, muscle biopsy were performed when IIM was suspected. We reviewed patients' medical records access results these tests if they had been previously. Results: elevation detected 10 patients (9.9%). identified one case anti-Jo-1 antibody-positive polymyositis cases possible myositis. MSA/MAA not found with high levels, except for anti-Jo-1-positive IIM. One patient elevated an overlapping muscular dystrophy. 19 (18.8%). A total 37% high-titer systemic diseases, while 63% low-titer antibodies, most whom no disease. Low serum 67.3% Comparison myasthenia composite (MGC) scores between low normal did show statistically significant difference. Conclusions: Our may raise awareness among neuromuscular specialists caring possibility associated myositis or other need assess levels. Although deficiency frequent, its impact on severity remains unclear, necessitating further investigation into immunological relevance.
Язык: Английский
Процитировано
0
International Journal of Molecular and Immuno Oncology, Год журнала: 2025, Номер 10, С. 45 - 49
Опубликована: Апрель 30, 2025
Immune checkpoint inhibitor (ICI)-induced myocarditis is a rare but fatal cardiotoxicity of ICIs. It an early toxicity ICIs, occurring within the first 30–40 days starting therapy. The exact mechanism unknown postulated to be due activation CD4+ and CD8+ T-lymphocytes in myocytes. Patients may have subtle changes electrocardiogram (ECG) echocardiography during therapy with some patients presenting acute left ventricular failure after or second dose ICI. We present case hepatocellular carcinoma developing severe fulminant ICI-induced 2 doses A high index suspicion needed detect on treatment protocol should include ECG troponin levels at each cycle initial phases treatment. mainstay steroids other cardiac support measures.
Язык: Английский
Процитировано
0
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Май 8, 2025
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various malignancies, particularly melanoma. However, immune-related adverse events (irAEs) pose significant challenges, in cases severe toxicity syndromes. One such life-threatening irAE is myocarditis, myositis, and myasthenia gravis (MMM) overlap syndrome, which occurs less than 1% patients but has in-hospital mortality rates ranging from 40 to 60%. Due its rarity complexity, early recognition a multidisciplinary approach are critical improving outcomes. We present single-institution case series four diagnosed with MMM syndrome following ICI therapy. Clinical presentation, laboratory findings, imaging, electrophysiological tests were analyzed confirm diagnosis. Therapeutic interventions-including corticosteroids, intravenous immunoglobulins (IVIG), plasma exchange (PLEX), tocilizumab, rituximab- evaluated terms efficacy clinical The onset varied 2 4 weeks after initiating Patients presented rapidly progressive symptoms, including ptosis, bulbar dysfunction, respiratory distress, myopathy, cardiac conduction abnormalities. Immunosuppressive therapy high-dose corticosteroids was initiated all cases. Additional immunomodulatory treatments (IVIG, PLEX, rituximab) administered based on deterioration autoimmune profile. Two achieved complete recovery, one remains maintenance immunosuppression, died due failure despite aggressive treatment. often fatal associated Early identification, immunosuppressive treatment, individualized therapeutic strategies essential optimize patient Further research needed refine diagnostic criteria, identify predictive biomarkers, establish standardized protocols.
Язык: Английский
Процитировано
0
Anti-Cancer Drugs, Год журнала: 2025, Номер unknown
Опубликована: Апрель 23, 2025
Immune checkpoint inhibitors (ICIs) have revolutionized advanced cancer treatment and prolonged survival; however, they are associated with several immune-related adverse events in up to 60% of patients, affecting various organ systems. A 73-year-old male patient metastatic melanoma was admitted left-sided ptosis, diplopia, head drop, proximal muscle weakness. The had been undergoing nivolumab ipilimumab, his symptoms emerged 4 days after receiving the second cycle immunotherapy regimen. He diagnosed as having ICI-related myositis, myasthenia gravis (MG), myocarditis based on electromyography, biopsy, antibody status, troponin level, cardiac evaluation. ICIs were withdrawn treated intravenous methylprednisolone, immunoglobulin, plasma exchange; treatment-refractory, necessitating long-term immunosuppression rituximab. Subsequently, he responded well, monotherapy resumed. has neurologically stable for months without any recurrence effects. MG, rare but can be severe potentially life-threatening. Therefore, early recognition immediate crucial improving prognosis. To best our knowledge, this is only case nivolumab- ipilimumab-induced triple overlap syndrome successfully
Язык: Английский
Процитировано
0
Supportive Care in Cancer, Год журнала: 2025, Номер 33(6)
Опубликована: Июнь 1, 2025
Язык: Английский
Процитировано
0